Financial Data and Key Metrics Changes - As of December 31, 2024, the company ended the year with $100.6 million in cash, cash equivalents, and investments, a decrease from $174.5 million at the end of 2023 [29] - Total revenue for 2024 was $138.1 million, compared to $101.2 million for 2023, attributed to collaborations with BMS, Moderna, Astellas, and Regeneron [32] - Total operating expenses for 2024 were $113.1 million, up from $107.7 million in 2023, primarily due to a $5 million milestone payment to AbbVie for CX-2051 [33] Business Line Data and Key Metrics Changes - The lead program, CX-2051, is a first-in-class masked ADC targeting EPCAM, which is currently in clinical trials [9] - CX-801, a masked version of interferon alpha, is also progressing well in Phase 1 trials, with initial data expected in the second half of 2025 [24] Market Data and Key Metrics Changes - The unmet need in colorectal cancer is significant, with over 1.9 million new cases annually and limited new treatments in the last two decades [13] - The company is focusing on late-line colorectal cancer patients who have received at least three prior systemic therapies, where current treatment options are inadequate [14] Company Strategy and Development Direction - The company is prioritizing its lead programs, CX-2051 and CX-801, to extend its cash runway to Q2 2026 and support key clinical milestones [8] - The strategy includes advancing antibody masking technology across multiple treatment modalities, including T cell engagers and cytokines [7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of CX-2051 and CX-801 to generate significant near-term value creation, with initial clinical data expected in 2025 [8] - The company remains committed to disciplined capital allocation and resource management to progress its promising pipeline [34] Other Important Information - The company achieved a $5 million milestone payment in its collaboration with Astellas for the STELLUS T cell engager program [25] - The company has decided not to continue the development of CX-904 in collaboration with Amgen, focusing instead on other promising masked T cell engagers [26] Q&A Session Summary Question: Update on CX-2051 patient enrollment and data expectations - Management anticipates a meaningful update on CX-2051, including initial safety profile characterization and potential antitumor activity data [41][42] Question: Timing for CX-801 and KEYTRUDA combination therapy - The initiation of the KEYTRUDA combination is expected in the second half of 2025, likely before data presentation [45] Question: Therapeutically active doses in CX-2051 trial - A significant number of patients will be treated with doses predicted to be within the therapeutic active range by the time data is shared [51] Question: Differential activity based on KRAS status or liver metastases - There is no obvious biology suggesting a connection between KRAS status or liver metastases and EPCAM expression; the study is enrolling a broad patient population [55] Question: Expression levels of EPCAM in colorectal cancer - EPCAM is highly expressed in colorectal cancer, and the clinical results are expected to validate this [61] Question: Focus on colorectal cancer for CX-2051 - The focus on colorectal cancer is due to high and consistent EPCAM expression, significant unmet need, and the drug's design being optimized for this indication [70][72]

Financial Data and Key Metrics Changes - As of December 31, 2024, the company ended the year with $100.6 million in cash, cash equivalents, and investments, a decrease from $174.5 million at the end of 2023 [29] - Total revenue for 2024 was $138.1 million, compared to $101.2 million for the corresponding period in 2023, attributed to collaborations with BMS, Moderna, Astellas, and Regeneron [32] - Total operating expenses for 2024 were $113.1 million, an increase from $107.7 million in 2023, primarily due to a $5 million milestone payment for CX-2051 [33] Business Line Data and Key Metrics Changes - The lead program, CX-2051, is a first-in-class ADC targeting EPCAM, with a focus on colorectal cancer, which has a significant unmet need [7][13] - CX-801, a masked version of interferon alpha, is also progressing well in early clinical trials, with plans to initiate combination therapy with KEYTRUDA in 2025 [24] Market Data and Key Metrics Changes - The global unmet need in colorectal cancer is significant, with over 1.9 million new cases annually and limited new treatments emerging in the last two decades [13] - The company is focusing on late-line CRC patients who have generally received at least three prior systemic therapies, indicating a high unmet need in this patient population [15][70] Company Strategy and Development Direction - The company is prioritizing its lead programs, CX-2051 and CX-801, to extend its cash runway to Q2 2026 and support key clinical milestones [8][29] - The strategy includes a focus on antibody masking technology and collaborations with major pharmaceutical companies to enhance its pipeline [7][25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the initial clinical data for CX-2051 and CX-801 expected in 2025, which could drive significant near-term value creation [8][28] - The company remains committed to disciplined capital allocation and resource management to progress its promising pipeline [34] Other Important Information - The company achieved a $5 million milestone in its collaboration with Astellas, indicating ongoing progress in its partnerships [31][25] - The company is not pre-selecting patients based on EPCAM expression or other disease characteristics in its Phase 1 study for CX-2051, aiming to characterize the drug across the full CRC population [15][56] Q&A Session Summary Question: Update on CX-2051 patient enrollment and data expectations - Management anticipates a meaningful update including initial safety profile characterization and potential antitumor activity data [41][42] Question: Timing for CX-801 and KEYTRUDA combination therapy - The initiation of the KEYTRUDA combination is expected in the second half of the year, likely before data presentation [45] Question: Therapeutically active doses in CX-2051 trial - A significant number of patients will be treated with doses predicted to be within the therapeutic active range by the time data is shared [51] Question: Expectations regarding KRAS status and liver metastases - There is no obvious biology suggesting a connection between KRAS status and EPCAM expression; the study aims to enroll a broad patient population [55] Question: Expression levels of EPCAM in CRC - EPCAM is highly expressed in colorectal cancer, and the clinical results are expected to validate this [61] Question: Focus on CRC for EPCAM targeting - The focus on CRC is due to its high and consistent EPCAM expression, significant unmet need, and the drug's design being optimized for this indication [70]

Financial Data and Key Metrics Changes - As of December 31, 2024, the company ended the year with $100.6 million in cash, cash equivalents, and investments, down from $174.5 million at the end of 2023 [21] - Total revenue for 2024 was $138.1 million, compared to $101.2 million for the corresponding period in 2023, attributed to collaborations with BMS, Moderna, Astellas, and Regeneron [22] - Total operating expenses for 2024 were $113.1 million, an increase from $107.7 million in 2023, primarily due to a $5 million milestone payment to AbbVie for the initiation of Phase I for CX2051 [23] Business Line Data and Key Metrics Changes - The lead program CX2051 is a first-in-class ADC targeting EpCAM, with a focus on colorectal cancer, which has a significant unmet need [6][10] - CX801, a masked probody interferon alpha-2b, is also progressing well in Phase I, with plans to initiate combination therapy with KEYTRUDA in 2025 [17] Market Data and Key Metrics Changes - The global unmet need in colorectal cancer is significant, with over 1.9 million new cases annually and limited new treatments emerging over the last two decades [10] - The company is focusing on late-line colorectal cancer patients who have generally received at least three prior systemic therapies, where current treatment options are inadequate [11] Company Strategy and Development Direction - The company is prioritizing its lead programs, CX2051 and CX801, to extend its cash runway to Q2 2026 and support key clinical milestones [6][20] - The strategy includes leveraging partnerships for research collaborations, with a recent $5 million milestone achieved in the Astellas collaboration [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the initial clinical data for CX2051 and CX801 expected in 2025, which could drive significant near-term value creation [7][20] - The company remains committed to addressing the high unmet need in oncology, particularly in colorectal cancer, and is focused on delivering differentiated cancer therapies [5][54] Other Important Information - The company has streamlined its organization to focus on lead programs and has a strong track record of achieving milestones in collaborations [21][22] - The Phase I study of CX2051 is being conducted entirely in the metastatic colorectal cancer setting, with a focus on broad patient enrollment to characterize the drug's efficacy [51] Q&A Session Summary Question: Update on CX2051 patient enrollment and data expectations - Management anticipates a meaningful update including initial safety profile characterization and anti-tumor activity assessment in the first half of 2025 [27][28] Question: Timing for CX801 and Pembroke combination initiation - The initiation of the KEYTRUDA combination is expected to proceed before data presentation, with initial data anticipated by the end of the year [31][32] Question: Therapeutically active doses in CX2051 trial - A significant number of patients will be treated with doses predicted to be within the therapeutic active range by the time data is shared [38] Question: Expectations regarding KRAS status and liver metastases - The company is enrolling a broad patient population to characterize the drug across the full CRC population, with no current expectations of differential activity based on KRAS status or liver metastases [42] Question: Focus on colorectal cancer for CX2051 - The focus on CRC is driven by high and consistent EpCAM expression levels and a significant unmet need in this patient population [54][55]

Core Insights - CytomX Therapeutics is advancing its lead program, CX-2051, in a Phase 1a study for advanced colorectal cancer, with initial clinical data expected in the first half of 2025 [1][2][3] - The company reported a cash position of $100.6 million as of December 31, 2024, which is projected to extend its cash runway into Q2 2026 [9][15] - Total revenue for 2024 was $138.1 million, a significant increase from $101.2 million in 2023, driven by collaborations with major pharmaceutical companies [10][11] Pipeline Program Updates - CX-2051 is a masked EpCAM-targeting antibody-drug conjugate (ADC) designed to address unmet needs in colorectal cancer, where EpCAM is expressed in over 90% of cases [2][6] - The Phase 1 study of CX-2051 began in April 2024, focusing on advanced metastatic colorectal cancer patients who have received multiple prior therapies [6] - CX-801, another program, is in Phase 1a for advanced melanoma, with initial translational data expected in the second half of 2025 [1][5][14] Financial Performance - Operating expenses for 2024 were $113.1 million, up from $107.7 million in 2023, primarily due to a $5 million milestone payment to AbbVie for CX-2051 [11][12] - Research and development expenses increased to $83.4 million in 2024, reflecting the costs associated with advancing CX-2051 [12] - The company reported a net income of $31.9 million for 2024, compared to a loss of $0.6 million in 2023, indicating a turnaround in financial performance [20] Corporate Strategy - In January 2025, CytomX announced a 40% reduction in organizational headcount to focus resources on CX-2051 and improve cost structure [15] - The company has established strategic collaborations with several leading oncology firms, including Bristol Myers Squibb, Amgen, Astellas, Regeneron, and Moderna [16]

Core Insights - CytomX Therapeutics reported its 2024 financial results and provided a business update, emphasizing the advancement of its clinical pipeline and the prioritization of CX-2051 for colorectal cancer treatment [1][2][11]. Financial Performance - Total revenue for 2024 was $138.1 million, an increase from $101.2 million in 2023, primarily driven by collaborations with Bristol Myers Squibb, Moderna, Astellas, and Regeneron [11]. - Operating expenses rose to $113.1 million in 2024 from $107.7 million in 2023, largely due to a $5 million milestone payment to AbbVie for the CX-2051 program [12][13]. - The company ended 2024 with cash, cash equivalents, and investments totaling $100.6 million, down from $174.5 million at the end of 2023 [10]. Clinical Pipeline Updates - CX-2051, a masked EpCAM-targeting ADC, is the lead program, currently in Phase 1a study for advanced colorectal cancer, with initial data expected in the first half of 2025 [6][7][3]. - The Phase 1 study of CX-2051 began in April 2024, focusing on patients with advanced metastatic colorectal cancer who have received multiple prior therapies [7]. - CX-801, another program, is expected to present Phase 1a translational data in advanced melanoma in the second half of 2025 [8]. Strategic Priorities - The company aims to extend its cash runway into Q2 2026 through cost reductions and focused clinical development, following a 40% reduction in organizational headcount announced in January 2025 [15][16]. - CytomX has established collaborations with major oncology players, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, to enhance its research and development efforts [15][16].

Financial Performance - Total revenue for 2024 was $138.1 million, an increase of 36.4% compared to $101.2 million in 2023[14] - The company reported a net income of $31.9 million for 2024, compared to a net loss of $0.6 million in 2023[24] Research and Development - Research and development expenses increased to $83.4 million in 2024, up from $77.7 million in 2023, primarily due to a $5.0 million milestone payment to AbbVie[16] - CX-2051 is the lead program, currently in Phase 1a study for advanced colorectal cancer, with initial data expected in 1H 2025[2] - The Phase 1 study of CX-2051 is ongoing, with a favorable tolerability profile and doses predicted to be therapeutically active achieved[11] - Initial Phase 1a translational data for CX-801 in advanced melanoma is anticipated in 2H 2025[2] Cash and Investments - CytomX ended 2024 with $100.6 million in cash, cash equivalents, and investments, down from $174.5 million at the end of 2023[14] - Cash and cash equivalents increased significantly from $17,171 million in 2023 to $38,052 million in 2024, representing a growth of about 121.5%[26] - The company expects its cash runway to extend into Q2 2026 due to cost reductions and focused clinical development[12] Organizational Changes - CytomX announced a 40% reduction in organizational headcount in January 2025 to focus resources on CX-2051[12] Assets and Liabilities - Total current assets decreased from $182,936 million in 2023 to $107,305 million in 2024, a decline of approximately 41.3%[26] - Total liabilities decreased from $249,239 million in 2023 to $120,989 million in 2024, a reduction of approximately 51.4%[26] - Deferred revenues, current portion dropped from $132,267 million in 2023 to $67,201 million in 2024, a decrease of about 49.3%[26] - The accumulated deficit improved from $(723,448) million in 2023 to $(691,579) million in 2024, indicating a reduction of approximately 4.4%[26] - Total stockholders' deficit decreased from $(47,447) million in 2023 to $(456) million in 2024, a significant improvement of about 99.0%[26] Other Financial Metrics - Short-term investments saw a decline from $157,338 million in 2023 to $62,571 million in 2024, a decrease of approximately 60.3%[26] - Operating lease right-of-use asset decreased from $12,220 million in 2023 to $8,136 million in 2024, a decline of about 33.4%[26] - Accounts payable decreased from $1,458 million in 2023 to $1,088 million in 2024, a reduction of approximately 25.3%[26] - Accrued liabilities decreased from $17,599 million in 2023 to $12,338 million in 2024, a decline of about 30.0%[26] - A $5 million milestone payment was triggered by Astellas advancing a program to GLP toxicology studies in February 2025[12]

Clinical Development and Pipeline - The company is developing a clinical-stage pipeline of novel, conditionally activated biologics targeting cancer, with a focus on localized therapies to minimize systemic toxicity [21]. - The lead program, CX-2051, is a conditionally activated ADC targeting EpCAM, currently in Phase 1 for advanced metastatic colorectal cancer, with initial data expected in the first half of 2025 [27][34]. - CX-801, a masked version of interferon alpha-2b, is in Phase 1 for advanced melanoma, with initial data anticipated in the second half of 2025 [30][38]. - The IND for both CX-2051 and CX-801 was approved by the FDA in January 2024, allowing clinical trials to proceed [34][38]. - CX-904, a PROBODY TCE targeting EGFR and CD3, has been discontinued from further development due to strategic decisions [29]. - The PROBODY platform is designed to activate therapeutics selectively within the tumor microenvironment, potentially increasing the therapeutic index and reducing systemic toxicity [22][40]. - CX-2051 is armed with a cytotoxic payload (CAMP59), a camptothecin-based topoisomerase-1 inhibitor, which has a long history in cancer treatment [32]. - CX-801 has shown preclinical tolerability at doses over 100-fold higher than unmasked interferon alpha-2b, indicating a favorable safety profile [37]. - The company aims to address significant unmet needs in oncology by advancing first-in-class therapies against validated targets with high therapeutic potential [27]. - The company has experienced production failures with a contract manufacturer for CX-2051, which may affect clinical trial timelines [78]. - The company initiated a first-in-human Phase 1 clinical trial with CX-904 in 2022, but cannot assure reaching an acceptable or tolerable dose for CX-2051 or CX-801 [190]. - Clinical trials may face risks related to severe adverse side effects, which could lead to suspension or termination of trials and affect regulatory approvals [192]. - The company is exposed to risks associated with conducting clinical trials outside the U.S., including potential non-acceptance of foreign data by the FDA [199]. - A contract manufacturer in China experienced production failures for CX-2051 starting in October 2023, which could disrupt clinical trials [204]. - The company relies on third-party manufacturers for clinical trial materials, with most being sole source suppliers, increasing the risk of supply interruptions [204]. - Patient enrollment in clinical trials is affected by various factors, including the severity of the disease and competition from other trials [198]. - The company may face significant delays in clinical trials if patient enrollment is insufficient due to ethical concerns or competing therapies [198]. - The potential passage of the BIOSECURE Act could restrict collaborations with certain foreign biotechnology companies, impacting manufacturing and supply [201]. - The company is facing challenges in scaling up manufacturing for its product candidates, which could delay clinical trials and commercialization [208]. - The PROBODY platform is being utilized to develop a pipeline of product candidates, including cancer immunotherapies and bispecific antibodies, aimed at reducing toxic effects associated with traditional therapies [209]. - There is uncertainty regarding the therapeutic effectiveness of the PROBODY platform, as it may not perform as expected in human subjects [210]. - The company has limited understanding of the pharmacology and immunogenicity of PROBODY therapeutics, which may affect their safety and efficacy [211]. - The regulatory approval process for conditionally activated therapeutics is complex and may result in delays or additional requirements for clinical trials [214]. Collaborations and Partnerships - The company has established collaborations with major biopharmaceutical partners including Amgen, Bristol Myers Squibb, and Regeneron to enhance its research and development capabilities [26][30]. - The Astellas Agreement resulted in an upfront payment of $80 million, with potential future milestones totaling approximately $1.2 billion [59]. - Astellas initiated GLP toxicology studies for the second collaboration target, triggering a $5 million milestone payment in the first quarter of 2025 [61]. - Under the Amgen Agreement, the company is eligible to receive up to $950 million in milestone payments if all options are exercised [56]. - The company has entered into several collaborations since 2013, including with Amgen and Astellas, to extend the reach of its technology and secure non-dilutive capital [52]. - The company continues to collaborate with Bristol Myers Squibb on PROBODY therapeutics for up to five oncology targets, with the research period projected to end in April 2025 [65]. - The Company has no further obligations related to a deprioritized target under the collaboration with Bristol Myers Squibb, reallocating the remaining unrecognized transaction price to other performance obligations [68]. - The Company is responsible for conducting preclinical development of PROBODY therapeutics against selected targets during the research period under the BMS agreement [65]. - The company is leveraging its PROBODY therapeutic platform in collaborations with both Moderna and Regeneron to develop innovative cancer therapies [70][74]. - The Moderna Agreement includes an upfront payment of $35 million, with potential future milestone payments of up to $1.2 billion for all Moderna Licensed Products [73]. - The Regeneron Agreement involves an upfront payment of $30 million and milestone payments of up to approximately $0.8 billion for initial collaboration programs, with additional potential payments of up to $1.2 billion for further programs [76]. - The ImmunoGen 2019 License includes potential milestone payments of up to $320 million for regulatory approval and commercial milestones, with royalties on product sales ranging from mid-to-high single digits percentages [84]. - The Company is eligible to receive approximately $1.3 billion in contingent payments for development, regulatory, and sales milestones for ongoing collaboration programs as of December 31, 2024 [69]. - Under the Amendment 1 to the BMS agreement, Bristol Myers Squibb made an upfront payment of $200 million and the Company is entitled to tiered mid-single to low double-digit percentage royalties from potential future sales [64]. - Collaborations with major biopharmaceutical companies, such as AbbVie and Bristol Myers Squibb, are crucial for the development of PROBODY therapeutics, but recent terminations of agreements pose risks [217]. - In January 2023, the company announced topline results for CX-2029, but AbbVie decided not to continue its development, leading to the company's decision to terminate the program [220]. Financial Performance and Funding - The company reported research and development expenses of $83.4 million for the year ended December 31, 2024, compared to $77.7 million for 2023, indicating a year-over-year increase of approximately 8.9% [168]. - As of December 31, 2024, the company had an accumulated deficit of $691.6 million, down from $723.4 million in 2023, reflecting a reduction in losses [171]. - The company has not generated any revenue from product sales and does not expect to do so for the foreseeable future, anticipating continued significant operating losses [173]. - In January 2025, the company announced a restructuring that will reduce its workforce by approximately 40% to preserve capital and focus on high-priority programs [174]. - The company expects to need to raise substantial additional funds to advance the development of its product candidates, with the potential for market conditions to complicate fundraising efforts [174]. - The company has financed operations primarily through sales of common stock and collaboration agreements, including those with Regeneron and Moderna in late 2022 [177]. - Future funding will be sought through collaborations, equity offerings, or debt financing, but the ability to raise funds may be limited due to declining stock prices [177]. - The company has no products on the market and relies on obtaining regulatory approvals for product candidates to achieve profitability [182]. - The company has a history of operating losses and may never achieve profitability, which could adversely affect the market value of its common stock [171]. Regulatory Environment - The company is actively pursuing regulatory approvals for its product candidates, which must undergo extensive preclinical and clinical studies before receiving FDA approval through the Biologics License Application (BLA) process [102][104]. - The FDA's approval process for biologics involves multiple phases, including preclinical studies, clinical trials, and compliance with good manufacturing practices (cGMPs) [105][109]. - The FDA aims to complete a standard review of an original BLA within ten months after the filing date, or within six months for applications qualifying for Priority Review [113]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) as a condition of BLA approval to ensure that the benefits of the drug outweigh its risks [118]. - The PMA process for companion diagnostics can take several years and requires extensive pre-clinical and clinical data to establish safety and effectiveness [123]. - A product candidate may be eligible for Fast Track designation if it addresses unmet medical needs for serious or life-threatening conditions, allowing for more frequent interactions with the FDA [127]. - Products receiving Accelerated Approval may be subject to expedited withdrawal procedures if confirmatory studies are not conducted in a timely manner [131]. - Patent term restoration under the Hatch-Waxman Act can extend patent life by up to five years, but cannot exceed a total of 14 years from the product candidate's approval date [132]. - The FDA may deny PMA approval based on deficiencies in the application, requiring additional clinical trials that can delay the approval process [124]. - Companion diagnostics must obtain marketing clearance or approval from the FDA prior to commercial distribution, and their approval is often required contemporaneously with the therapeutic product [121]. - The FDA's goal for Priority Review is to take action on the marketing application within six months of the filing date, compared to ten months under standard review [130]. - The FDA may inspect manufacturing facilities and clinical sites to ensure compliance with regulatory standards before approving a BLA [115]. - The Affordable Care Act established a 12-year exclusivity period for reference biological products, during which biosimilar applications cannot be approved [134]. - Orphan Drug Designation can provide up to 7 years of exclusivity for products approved for rare diseases, with additional benefits such as tax credits and waivers of FDA user fees [137]. - Pediatric exclusivity can extend existing exclusivity periods by 6 months if a pediatric study is completed as per FDA request [135]. - The Pediatric Research Equity Act mandates pediatric studies for most therapeutic candidates, requiring assessments for safety and effectiveness in relevant pediatric subpopulations [139]. - The ACA has led to increased Medicaid rebates and established annual fees on manufacturers of certain branded prescription drugs, impacting overall healthcare costs [150]. - The American Rescue Plan Act of 2021 eliminated the Medicaid drug rebate cap starting January 1, 2024, which was previously set at 100% of a drug's average manufacturer price [152]. - The FDA may withdraw approval of a biologic product if regulatory compliance is not maintained post-approval, which can include mandatory revisions to labeling or additional studies [143]. - The FDA closely regulates marketing and promotion of drug products, allowing only claims that are approved and in accordance with the product's labeling [144]. - Orphan drugs in the European Union can enjoy up to 10 years of market exclusivity unless a competitor demonstrates clinical superiority [148]. - The approval process for clinical trials and product licensing varies significantly across jurisdictions, impacting the timeline for market entry [145]. Market Competition and Intellectual Property - The company faces substantial competition in the biopharmaceutical sector, particularly in antibody-drug conjugates (ADCs), T-cell engaging therapies (TCEs), and cytokine therapeutics, with numerous large and mid-sized companies actively developing similar products [87][88][89][90][91]. - As of January 2025, the company's patent portfolio includes at least 250 granted patents and at least 400 pending patent applications, indicating a strong intellectual property position [95]. - The company relies on a combination of patent protection, trade secret protection, and data exclusivity to maintain its competitive edge in the market [93][94]. - The company anticipates that its currently issued patents will expire between 2028 and 2042, with pending applications potentially expiring between 2028 and 2045, depending on patent term extensions [100]. - The company is prepared to adapt its intellectual property strategy as new technologies are developed and competitive pressures evolve, including filing additional patent applications as necessary [99]. - The competitive landscape includes major players such as AbbVie, Amgen, and Roche, which may have greater financial and technical resources, posing a risk to the company's market position [92]. - The company emphasizes the importance of efficacy, safety, and convenience of its product candidates as key factors for success in the market [92]. - The company is committed to protecting its proprietary technology and innovations through rigorous patent and trade secret strategies, ensuring its competitive advantage in the biopharmaceutical industry [93][94].

SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In additi ...

CytomX Therapeutics (CTMX) , a clinical-stage oncology company, is slated to report its fourth-quarter 2024 earnings results on March 6, after market close. The company leverages its proprietary PROBODY therapeutic platform to discover and develop safer, more effective therapies for the treatment of cancer.See the Zacks Earnings Calendar to stay ahead of market-making news.The Zacks Consensus Estimate for CTMX’s loss per share in the to-be-reported quarter is currently pegged at 20 cents. CytomX also recogn ...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and P ...